PMID: 11337165May 5, 2001Paper

Formulation of a reservoir-type testosterone transdermal delivery system

International Journal of Pharmaceutics
M K KimD D Kim

Abstract

A reservoir-type transdermal delivery system of testosterone (TS) was developed using an ethanol/water (70:30) cosolvent system as the vehicle. The maximum permeation rate achieved by 70% (v/v) of ethanol was further increased from 2.69 to 47.83 microg/cm(2)/h with the addition of 1.0% dodecylamine as the skin permeation enhancer. The permeation rate of TS through the ethylene vinyl acetate (EVA) membrane was observed to increase as the vinyl acetate content in the copolymer increased. Addition of 1.0% (w/w) gelling agent, hydroxypropyl methlycellulose (HPMC), in the reservoir formulation resulted in desirable rheological properties with an insignificant effect on the skin permeation rate of TS. Thus, a new transdermal delivery system for TS was formulated using EVA membrane coated with a pressure-sensitive adhesive (Duro-Tak 87-2510) and HPMC as a gelling agent. This experimental patch showed comparable plasma concentration profiles in the in vivo study when compared with a commercial product, Androderm(R). Moreover, the results suggested the possibility of further enhancing the permeation rate of TS by controlling the composition of the reservoir formulation.

References

Sep 1, 1989·The Journal of Clinical Endocrinology and Metabolism·J J StĕpánD J Baylink
Feb 1, 1987·Endocrine Reviews·A D MooradianS G Korenman
Aug 1, 1984·Journal of Pharmaceutical Sciences·E R Cooper
Nov 1, 1996·Journal of Pharmaceutical Sciences·D D KimY W Chien
May 17, 2000·The Journal of Pharmacy and Pharmacology·M K KimD D Kim

❮ Previous
Next ❯

Citations

Jun 30, 2011·European Journal of Drug Metabolism and Pharmacokinetics·Kalpana SwainSubrata Mallick
Mar 22, 2005·International Journal of Pharmaceutics·Ramesh PanchagnulaSateesh Khandavilli
Aug 27, 2009·Therapeutics and Clinical Risk Management·Nazem BassilJohn E Morley
May 26, 2010·Clinics in Geriatric Medicine·Nazem Bassil, John E Morley
Aug 4, 2009·Journal of Pharmaceutical and Biomedical Analysis·József PappRomána Zelkó
Mar 14, 2008·International Journal of Pharmaceutics·Wen HeMian Zhang
May 9, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Marie-Laure LeichtnamRichard H Guy
Apr 16, 2005·Drug Development and Industrial Pharmacy·Hong ZhaoDae-Duk Kim
Feb 27, 2003·Drug Development and Industrial Pharmacy·Na-Mi AnChi-Ho Lee
Oct 21, 2011·Drug Development and Industrial Pharmacy·P Gansen, M Dittgen
Mar 31, 2011·Drug Development and Industrial Pharmacy·Satyanarayan PattnaikSubrata Mallick
Jul 7, 2009·The Journal of Veterinary Medical Science·Norio YamagishiYoshihisa Naito
Aug 4, 2004·International Journal of Pharmaceutics·Gregorios G AgyralidesDimitrios M Rekkas
Jun 27, 2008·Colloids and Surfaces. B, Biointerfaces·Naseem Ahmad CharooZiyaur Rahman
Nov 27, 2018·Bioanalysis·Isaac Mall, Florin Marcel Musteata
Jun 7, 2006·Pharmaceutical Research·Marie-Laure LeichtnamRichard H Guy
Sep 24, 2005·Pharmaceutical Development and Technology·Naseem Ahmad CharooZiyaur Rahman
Mar 25, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·S RamkanthDinesh Babu
Jul 2, 2019·Acta Pharmaceutica : a Quarterly Journal of Croatian Pharmaceutical Society and Slovenian Pharmaceutical Society, Dealing with All Branches of Pharmacy and Allied Sciences·Othman A Al HanbaliAbdul Hameed
Jan 15, 2008·Trends in Biotechnology·Dolores D Mruk, C Yan Cheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.